First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan

Trial Details

NCT ID
NCT06667167
Phase
PHASE2
Sponsor
Nir Peled
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Induction Carboplatin
Locations (sample)
  • Jerusalem, Israel, Israel|31.76904,35.21633

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically or cytologically confirmed dia…
  • The participant has not been previously treated with systemic therapy for ES SCLC (i.e., the disease is treatment naïve).
  • Note: Participants previously treated for limited SCLC will be allowed with disease-free survival (DFS) of 6 months after completion of all treatment.
  • Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →